This protocol was submitted by the author(s) of the original paper via Bio-protocol's "Request a Protocol" feature.
Original Research Paper Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
DOI: 10.1126/science.abf3363
Science , Feb 5, 2021
Related protocols in the same article
Clinical Trial Design: Summary, Recipient Eligibility Criteria, Donor Selection Criteria, Donor/Recipient Seromatching, and Study Conduct
Diwakar Davar    
Original Research Paper
Last updated date: Feb 11, 2021 View: 299


How to cite: Readers should cite both the Bio-protocol article and the original research article where this protocol was used:
1. Davar, D. (2021). Clinical Trial Design: Summary, Recipient Eligibility Criteria, Donor Selection Criteria, Donor/Recipient Seromatching, and Study Conduct. Bio-protocol. bio-protocol.org/prep834.
2. Davar, D., Dzutsev, A., McCulloch, J., Rodrigues, R., Chauvin, J., Morrison, R., Deblasio, R., Menna, C., Ding, Q., Pagliano, O., Zidi, B., Zhang, S., Badger, J., Vetizou, M., Cole, A., Fernandes, M., Prescott, S., Costa, R., Balaji, A., Morgun, A., Vujkovic-Cvijin, I., Wang, H., Borhani, A., Schwartz, M., Dubner, H., Ernst, S., Rose, A., Najjar, Y., Belkaid, Y., Kirkwood, J., Trinchieri, G. and Zarour, H.(2021). Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients. Science 371(6529). DOI: 10.1126/science.abf3363
Copyright: Content may be subjected to copyright.
 Q&A
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.